Treatment of acute hepatitis C in an HIV-positive man with pegylated interferon and ribavirin for 24 weeks.
An epidemic of acute hepatitis C is emerging among HIV-infected men who have sex with men (MSM), with a growing number of cases reported in the MSM population in the United States and Europe. We report a case of a 47-year-old HIV-infected MSM who sexually contracted acute hepatitis C and was treated with pegylated interferon and ribavirin for 24 weeks. After 4 weeks of therapy, the patient's HCV RNA level became undetectable and remained undetectable 1 year after the 24-week treatment course.
Rafiq
Nila
N
Carriero
Damaris
D
Uriel
Allison
A
Dieterich
Douglas T
DT
D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000635:transmission; D018451:Homosexuality, Male / Q000523:psychology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b